Supervised injection site

Supervised injection sites (SIS) are medically supervised facilities designed to provide a hygienic environment in which people are able to consume illicit recreational drugs intravenously and prevent deaths due to drug overdoses. The legality of such a facility is dependent by location and political jurisdiction. Supervised injection sites are part of a harm reduction approach towards drug problems. The facilities provide sterile injection equipment, information about drugs and basic health care, treatment referrals, access to medical staff, and, at some facilities, counseling. Most programs prohibit the sale or purchase of recreational drugs at the facility. Supervised injection sites are also known as overdose prevention centers (OPC), supervised injection facilities, safe consumption rooms, safe injection sites, safe injection rooms, fix rooms, fixing rooms, safer injection facilities (SIF), drug consumption facilities (DCF), drug consumption rooms (DCRs), and harm reduction centers. "Shooting galleries" (the term "shooting" is slang for injecting drugs) have existed for a long time; there were illicit for-profit facilities in Sydney, Australia during the 1990s. Authors differentiated the legally sanctioned sites in Australia from those examples in the care they provide. While the operators of the shooting galleries exemplified in Sydney had little regard for the health of their clients, modern supervised injection facilities are a professionally staffed health and welfare service. The same journal describes the same facility in Australian context as "in general" may be defined as "legally sanctioned and supervised facilities designed to reduce the health and public order problems associated with illegal injection drug use" The legality of supervised injection is handled on a state-by state basis. New South Wales trialed a supervised injection site in Sydney in 2001, which was made permanent in 2010. Victoria also opened a supervised injection site in Melbourne in 2018 on a trial basis; in 2020 the trial was extended for a further three years and a second site approved.